Cholesterol lowering effect of dietary weight loss and orlistat treatment - Efficacy and limitations

Department of Internal Medicine II, Technical University of Munich, Munich, Germany.
Alimentary Pharmacology & Therapeutics (Impact Factor: 5.73). 07/2004; 19(11):1173-9. DOI: 10.1111/j.1365-2036.2004.01966.x
Source: PubMed


Orlistat reduces energy uptake by the impairment of fat digestion and some evidence indicates it also lowers plasma cholesterol.
To examine total, low-density lipoprotein- and high-density lipoprotein cholesterol during a weight reducing regimen, and assess the effect of orlistat in lowering cholesterol levels independent of its weight reducing efficacy.
A total of 448 patients with elevated cholesterol according to cardiovascular risk factors entered a 2 week single-blind run-in period on a hypocaloric diet. Of 384 patients were subsequently assigned double-blind treatment with orlistat (3 x 120 mg/day) or placebo for 6 months in conjunction with the hypocaloric diet.
Weight loss in the orlistat group was 7.4 kg vs. 4.9 kg with placebo. Total and low-density lipoprotein cholesterol decreased by 25-30 mg/dL vs. 10-15 mg/dL with placebo. Reduction of cholesterol with orlistat was significantly greater than anticipated from weight loss alone. In patients with cardiovascular risk factors entering the study with lower cholesterol values orlistat was also superior to placebo. On the contrary, reduction of cholesterol concentrations never exceeded 20%.
Orlistat has a cholesterol lowering efficacy independent of its weight reducing effect. Because of the limited therapeutic effectiveness, patients at high cardiovascular risk should receive rather early additional cholesterol lowering medication during weight loss programmes.

Download full-text


Available from: Gerald Klose, Nov 07, 2014
22 Reads
  • Source
    • "Clinical studies in obese patients acknowledged the contribution of an additional, yet to be identified, mechanism(s) to the decreased levels of plasma cholesterol. Erdmann and colleagues have reported that orlistat prevents the digestion of approximately 30% of the ingested fat (Erdmann et al., 2004), which is associated with 15–25% reduction in cholesterol plasma levels (Erdmann et al., 2004; Mittendorfer et al., 2001). The authors of these studies concluded that orlistat lowers plasma cholesterol beyond its effect on weight loss associated with digestion inhibition. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The known mechanism by which orlistat decreases the absorption of dietary cholesterol is by inhibition of intestinal lipases. The aim of this study was to investigate the ability of orlistat to limit cholesterol absorption by inhibition of the cholesterol transport protein Niemann-Pick C1-like 1 (NPC1L1) as another mechanism of action. In situ rat intestinal perfusion studies were conducted to study the effect of orlistat on jejunal cholesterol absorption. Inhibition kinetic parameters were calculated from in vitro inhibition studies using Caco2 and NPC1L1 transfected cell lines. The in situ studies demonstrated that intestinal perfusion of orlistat (100µM) was able to reduce cholesterol absorption by three-fold when compared to control (i.e. in the absence of orlistat, P<0.01). In vitro studies using Caco2 cells demonstrated orlistat to reduce the cellular uptake of cholesterol by 30%. Additionally, orlistat reduced the cellular uptake of cholesterol in dose dependent manner in NPC1L1 transfected cell line with an IC50=1.2µM. Lineweaver-Burk plot indicated a noncompetitive inhibition of NPC1L1 by orlistat. Beside the already established mechanism by which orlistat reduces the absorption of cholesterol, we demonstrated for the first time that orlistat limits cholesterol absorption by the inhibition of NPC1L1 transport protein. Copyright © 2015. Published by Elsevier B.V.
    European journal of pharmacology 06/2015; 762. DOI:10.1016/j.ejphar.2015.05.060 · 2.53 Impact Factor
  • Source
    Article: REVISIONES
  • [Show abstract] [Hide abstract]
    ABSTRACT: Orlistat is an inhibitor of gastrointestinal lipases and, therefore, prevents the absorption of dietary fat. This agent reduced weight in obese adults and adolescents with or without co-morbidities (including type 2 diabetes mellitus, hypercholesterolemia, hypertension, metabolic syndrome) who received up to 4 years of therapy in conjunction with a hypocaloric diet. In obese patients, orlistat in combination with a hypocaloric diet improved metabolic risk factors and reduced the risk of developing type 2 diabetes. Furthermore, this agent was cost effective in patients with obesity, particularly those with type 2 diabetes. Orlistat is generally well tolerated, with gastrointestinal adverse events being most commonly reported. Orlistat, in addition to lifestyle and dietary intervention, is thus an attractive option for the treatment of patients with obesity, especially those with associated co-morbidities or at risk of developing type 2 diabetes.
    Treatments in Endocrinology 02/2005; 4(2):127-9. DOI:10.2165/00024677-200504020-00006
Show more